These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 11193173

  • 1. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
    Kahle PJ, Neumann M, Ozmen L, Haass C.
    Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173
    [Abstract] [Full Text] [Related]

  • 2. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL.
    Proc Natl Acad Sci U S A; 2002 Jun 25; 99(13):8968-73. PubMed ID: 12084935
    [Abstract] [Full Text] [Related]

  • 3. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.
    Proc Natl Acad Sci U S A; 2002 Aug 06; 99(16):10813-8. PubMed ID: 12122208
    [Abstract] [Full Text] [Related]

  • 4. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, Martin FL, Harriott P, Cookson MR, Allsop D.
    FASEB J; 2004 Aug 06; 18(11):1315-7. PubMed ID: 15180968
    [Abstract] [Full Text] [Related]

  • 5. Alpha-synuclein and Parkinson's disease.
    Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P.
    FASEB J; 2004 Apr 06; 18(6):617-26. PubMed ID: 15054084
    [Abstract] [Full Text] [Related]

  • 6. Synucleins in synaptic plasticity and neurodegenerative disorders.
    Clayton DF, George JM.
    J Neurosci Res; 1999 Oct 01; 58(1):120-9. PubMed ID: 10491577
    [Abstract] [Full Text] [Related]

  • 7. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
    Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK.
    J Neurosci; 2004 Aug 18; 24(33):7400-9. PubMed ID: 15317865
    [Abstract] [Full Text] [Related]

  • 8. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA, Harper JD, Lansbury PT.
    Nat Med; 1998 Nov 18; 4(11):1318-20. PubMed ID: 9809558
    [Abstract] [Full Text] [Related]

  • 9. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
    Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P, Hartmann T, Price DL, Lee MK.
    Proc Natl Acad Sci U S A; 2005 Feb 08; 102(6):2162-7. PubMed ID: 15684072
    [Abstract] [Full Text] [Related]

  • 10. Synoretin--A new protein belonging to the synuclein family.
    Surguchov A, Surgucheva I, Solessio E, Baehr W.
    Mol Cell Neurosci; 1999 Feb 08; 13(2):95-103. PubMed ID: 10192768
    [Abstract] [Full Text] [Related]

  • 11. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations.
    Li W, Hoffman PN, Stirling W, Price DL, Lee MK.
    J Neurochem; 2004 Jan 08; 88(2):401-10. PubMed ID: 14690528
    [Abstract] [Full Text] [Related]

  • 12. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J, Uversky VN, Fink AL.
    Biochemistry; 2001 Sep 25; 40(38):11604-13. PubMed ID: 11560511
    [Abstract] [Full Text] [Related]

  • 13. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
    Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C.
    J Neurosci; 2000 Sep 01; 20(17):6365-73. PubMed ID: 10964942
    [Abstract] [Full Text] [Related]

  • 14. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ.
    Exp Neurol; 2002 May 01; 175(1):35-48. PubMed ID: 12009758
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
    Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR.
    J Neurochem; 2003 Aug 01; 86(4):836-47. PubMed ID: 12887682
    [Abstract] [Full Text] [Related]

  • 17. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM.
    Exp Neurol; 2004 Jun 01; 187(2):279-88. PubMed ID: 15144854
    [Abstract] [Full Text] [Related]

  • 18. Alpha-synuclein: normal function and role in neurodegenerative diseases.
    Norris EH, Giasson BI, Lee VM.
    Curr Top Dev Biol; 2004 Jun 01; 60():17-54. PubMed ID: 15094295
    [Abstract] [Full Text] [Related]

  • 19. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
    Haywood AF, Staveley BE.
    BMC Neurosci; 2004 Apr 16; 5():14. PubMed ID: 15090075
    [Abstract] [Full Text] [Related]

  • 20. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
    Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D.
    Neuron; 2005 Jun 16; 46(6):857-68. PubMed ID: 15953415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.